<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698046</url>
  </required_header>
  <id_info>
    <org_study_id>13/03301-1</org_study_id>
    <nct_id>NCT02698046</nct_id>
  </id_info>
  <brief_title>Oral Iron Therapy in Chronic Heart Failure Patients</brief_title>
  <official_title>Oral Iron Therapy in Chronic Heart Failure Patients: a Randomized, Placebo-controlled and Double-blind Clinical Trial (Pilot Study) of Efficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is design to evaluate the effectiveness of oral iron therapy in patients with
      heart failure and identify the central and peripheral mechanisms involved in the improvement
      of functional capacity after intervention. The investigation includes subjective and
      objective measures on exercise performance and heart function after intervention, and the
      tolerability of oral iron treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled, double-blind and randomized clinical trial that will include
      patients with symptomatic stable chronic heart failure (New York Heart Association Functional
      Class II or III), with diagnosis of iron deficiency (ferritin &lt;100 ng / dL or ferritin
      between 100 - 300 ng / dL and transferrin saturation &lt;20%) followed in an outpatient clinic.
      The enrolled patients (n = 36) will be randomly allocated in the ratio 2:1 to treatment with
      60 mg of elemental iron orally (n = 24) or placebo administration (n = 12), 3 times daily for
      4 months. The primary outcome investigated will be an increase of the transferrin saturation
      ≥ 10 percentage points between baseline and after the intervention. Secondary outcomes of the
      study will be the change in iron stores, red blood cell indices, neurohumoral activation,
      left ventricular systolic function, functional capacity, mechanoreflex activity, and quality
      life score.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical parameter of serum transferrin saturation</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameter of hemoglobin in the hemogram analysis</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameter of serum ferritin</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of oxygen consumed at peak exercise during cardiopulmonary exercise testing</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mL/kg/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of oxygen consumed at anaerobic threshold during cardiopulmonary exercise testing</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mL/kg/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction of the left ventricle on doppler echocardiographic study</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameter of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) serum levels</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure results during mechanoreflex evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate results during mechanoreflex evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of oxygen consumed results during mechanoreflex evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mL/kg/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of physical, emotional, and overall dimensions domains of the Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>4 months</time_frame>
    <description>Score range 0 to 105 points</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biochemical parameter of serum urea</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical parameter of serum creatinine</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical parameter of serum sodium</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical parameter of serum potassium</measure>
    <time_frame>4 months</time_frame>
    <description>Unit of measure mg/dL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ferrous sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrous sulfate</intervention_name>
    <description>200mg of ferrous sulfate three times a day for 4 months</description>
    <arm_group_label>Ferrous sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo starch</intervention_name>
    <description>200mg of placebo starch three times a day for 4 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Both gender patients aged over 18 years;

          -  Diagnosis of chronic heart failure (identified by the use of Framingham criteria) for
             ≥ 6 months;

          -  New York Heart Association functional class II and III;

          -  Left ventricular ejection fraction ≤ 45%

          -  Regular attendance in an outpatient Heart Failure Clinic;

          -  Adequate therapeutic drug for heart failure syndrome based on beta-adrenergic blocker,
             angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and
             mineralocorticoid receptor blocker;

          -  Evidence of iron deficiency in biochemical analyses: ferritin values &lt; 100 ng/dL or
             between 100 ng/dL and 300 ng/dL, with transferrin saturation &lt; 20%;

          -  Hemoglobin value between 9,0 - 16 g/dL;

          -  Provide written informed consent.

        Exclusion criteria

          -  Recent device implant (in the last 3 months) or perspective of device implantation
             (conventional or multisite pacing) in the next 6 months;

          -  Known active infection, inflammatory disease or C-reactive protein &gt; 20 mg/dL

          -  Immunosuppressive therapy;

          -  In use of erythropoietin and/or current treatment with oral or intravenous iron;

          -  Clinically bleeding or blood transfusion in previous 3 months;

          -  Renal failure on dialysis;

          -  Hemoglobinopathies, hemochromatosis or active malignancy;

          -  Unstable angina pectoris or clinically significant uncorrected valvular disease,
             except mitral and tricuspid regurgitation secondary to ventricular dilatation;

          -  Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack
             within the last 3 months;

          -  Uncontrolled arterial hypertension;

          -  Evidence of comorbidity that features active systemic disease, i.e. liver disease,
             collagen disease and untreated hyperthyroidism or hypothyroidism;

          -  Pregnant or lactating women;

          -  Anaemia due to reasons other than iron deﬁciency (i.e. vitamin B12 deficiency);

          -  Recent admission for decompensated heart failure (last 3 months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaqueline RS Gentil, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaqueline RS Gentil, Master</last_name>
    <phone>+551633154577</phone>
    <email>jaqueline.gentil@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14000-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaqueline RS Gentil, Master</last_name>
      <phone>+551633154577</phone>
      <email>jaqueline.gentil@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Marcus V Simoes, PhD</last_name>
      <phone>+551636022791</phone>
    </contact_backup>
    <investigator>
      <last_name>Marcus Vinícius Simões, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro V Schwartzmann, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo EV Carvalho, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciana P Seabra, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Júlio C Crescêncio, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lourenço Gallo Junior, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.</citation>
    <PMID>19920054</PMID>
  </reference>
  <reference>
    <citation>Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010 Aug;31(15):1872-80. doi: 10.1093/eurheartj/ehq158. Epub 2010 Jun 21. Erratum in: Eur Heart J. 2011 May;32(9):1054.</citation>
    <PMID>20570952</PMID>
  </reference>
  <reference>
    <citation>Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011 Sep 13;58(12):1241-51. doi: 10.1016/j.jacc.2011.04.040.</citation>
    <PMID>21903058</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>February 28, 2016</last_update_submitted>
  <last_update_submitted_qc>February 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Jaqueline Rodrigues de Souza Gentil</investigator_full_name>
    <investigator_title>Master degree</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Iron</keyword>
  <keyword>Anemia</keyword>
  <keyword>Chronic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

